Abstract
Raynaud’s phenomenon (RP) is seen in over 95% of patients with SSc and is often the first symptom of the disease. Scleroderma vascular disease is secondary to an obliterative vasculopathy causing not only vasospasm but also structural disease of the involved vessels. Digital ulcers are representative of vascular involvement in scleroderma and occur in about 30–50% of patients with scleroderma. The primary goal in the management of RP is the prevention of digital ischemia through the use of non-pharmacological and pharmacological measures. In the setting of acute digital ischemia, rapid intervention using both treatment modalities is required. This case illustrates the problem of RP and digital ischemia and the approach to management.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Charkoudian N. Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans. J Appl Physiol. 2010;109(4):1221-1228.
Wigley FM. Vascular disease in scleroderma. Clin Rev Allergy Immunol. 2009;36:150-175.
Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine Baltimore. 1980;59:393-408.
Steen V, Denton CP, Pope JE, et al. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology Oxford. 2009;48(suppl 3):iii19-iii24.
Hummers LK, Wigley FM. Management of Raynaud’s phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am. 2003;29:293-313.
Allanore Y, Seror R, Chevrot A, et al. Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. Arthritis Rheum. 2007;56:2747-2754.
Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud’s phenomenon: a literature review and meta-analysis. Rheumatology Oxford. 2009;48:791-795.
Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44:1841-1847.
Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized, controlled trial. Arthritis Rheum. 2009;60:870-877.
Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980-2985.
Schiopu E, Hsu VM, Impens AJ, et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis. J Rheumatol. 2009;36:2264-2268.
Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994;120:199-206.
Gliddon AE, Doré CJ, Black CM, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum. 2007;56:3837-3846.
Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 1999;42:2646-2655.
Korn JH, Mayes M, Matucci-Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985-3993.
Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomized, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70(1):32-38.
Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol. 2008;35:1801-1808.
Bogoch ER, Gross DK. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol. 2005;32:642-648.
Taylor MH, McFadden JA, Bolster MD, Silver RM. Ulnar artery involvement in systemic sclerosis (scleroderma). J Rheumatol. 2002;29:102-106.
Van Beek AL, Lim PK, Gear AJ, et al. Management of vasospastic disorders with Botulinum toxin A. Plast Reconstr Surg. 2007;119:217-226.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag London Limited
About this chapter
Cite this chapter
Wigley, F.M., Wung, P.K. (2011). Painful Digital Ulcers in a Scleroderma Patient with Raynaud’s Phenomenon. In: Silver, R., Denton, C. (eds) Case Studies in Systemic Sclerosis. Springer, London. https://doi.org/10.1007/978-0-85729-641-2_10
Download citation
DOI: https://doi.org/10.1007/978-0-85729-641-2_10
Published:
Publisher Name: Springer, London
Print ISBN: 978-0-85729-640-5
Online ISBN: 978-0-85729-641-2
eBook Packages: MedicineMedicine (R0)